More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

Sanofi CEO Olivier Brandicourt has announced plans to retire, effective September 1, with Paul Hudson, head of Novartis' pharmaceutical division, taking the helm. With Sanofi facing competition in its diabetes-drug franchise and recent moves in...

The emergence of mega-contract development and manufacturing organizations (CDMOs), limited acquisition targets of CDMOs due to tight capacity, and burgeoning trade issues are key issues influencing deal-making in the CDMO market. Mergers and...

High-potency manufacturing and capabilities for early-stage development are among recent investment trends by contract development and manufacturing organizations/contract manufacturing organizations (CDMOs/CMOs) of intermediates and small-molecule...

The oncology drug market, the pharma industry's largest sector, is taking center stage at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago this week. A recent IQVIA analysis highlights the key trends, recent...

The pharmaceutical industry is in a wait-and-see mode as the UK tries to come up with a new Brexit plan that will mend internal division in the UK while still satisfying the EU. What is the impact on supply and pharma regulation? Brexit: where it...

Some members of Congress as well as Presidential candidates have proposed establishing a single-payer healthcare system in the US. A recent analysis by the Congressional Budget Office (CBO) examines the cost and benefits, including the impact for...

Pricing pressure and underperformance in the US generics market led several of the major generic-drug companies in 2018 to re-evaluate their businesses and put forth new strategies. Some companies say they are seeing signs of stabilization, but...

The European Parliament voted last month to allow manufacturing waivers to supplementary protection certificates (SPCs), a move supported by generics and biosimilars producers and manufacturers of active pharmaceutical ingredients (APIs), but...

Clarivate Analytics’ Cortellis Drugs to Watch 2019 Report identifies seven drugs that are set to enter the market in 2019 and achieve blockbuster status by 2023. Which drugs are projected to make the mark? Examing the potential blockbusters In...